Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.
Enter to win one of our amazing door prizes. Clinical Decision Making is giving away an Apple Watch Series 5 each day. Visit each vendor and enter for more chances to win. Only one entry per vendor page is allowed - invalid email address entries and duplicate entries will be deleted before the drawing each day.
Contact Information
Office Location & Contact
Portola Pharmaceuticals Inc.
270 E. Grand Avenue
South San Francisco, CA 94080
Phone: 650.246.7000
Fax: 650.246.7376
Email: contact@portola.com
Sales
- Gregg Wolf
Thrombosis Area Manager, NE
Phone: (516) 732-7835
Email: gwolf@portola.com
- Catherine Errickson
Thrombosis Area Manager, SE
Phone: (904) 294-4192
Email: cerrickson@portola.com
Investor Relations
- Jennifer Zibuda
Associate Director, International Relations
Email: jzibuda@portola.com
HEOR
- Terry Dettling
Associate Director, East Region
Phone: (828) 302-8521
Email: tdettling@portola.com
Market Access
- Elaine Crawford
Institutional Reimbursement & Access Manager
Phone: (609) 970-9159
Email: ecrawford@portola.com
National Accounts
- Natasa Sokolovich
Director, National Accounts
Phone: (412) 389-1649
Email: nsokolovich@portola.com